The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID‐19 patients with malignancy: A single‐center experience

Abstract

Undoubtedly, cancer patients have suffered the most from the COVID‐19 pandemic process. However, cancer is a heterogeneous disease, and each patient has responded differently to COVID‐19. We aimed to describe the clinical characteristics and outcomes of patients with cancer and COVID‐19. We retrospectively reviewed 45 cancer patients hospitalized in the Cerrahpaşa Medical Faculty COVID‐19 department from March 23 to October 23, 2020. We analyzed the demographic characteristics, symptoms, laboratory findings, treatment, prognosis, and cancer subtypes of patients and mortality who were hospitalized for COVID‐19. Between March 23 and October 23, 2020, 45 hospitalized cancer patients who had laboratory‐confirmed COVID‐19 infection were included, with a median age of 60 years (range: 23–92). Patients were divided into two groups a survivor and a non‐survivor. Symptoms, demographic information, comorbidities, treatments for COVID‐19, and laboratory findings of the two groups were evaluated separately. Two parameters were found, which showed a significant difference between non‐survivors and survivors displaying a disadvantage for COPD and low platelet count ( p = 0.044–0.038). The mortality rate of all patients was 66%. The presence of comorbidities such as COPD and low platelet count in cancer patients with COVID‐19 infection may draw the attention of physicians.

Clinical characteristics and mortality predictors of patients with cancer hospitalized by COVID-19 in a pediatric third-level referral center

“…Thrombocytopenia in cancer children is understudied, but a low count in adults was associated with coagulation disorders that lead to organ failure and death in patients with severe COVID-19 ( 13 – 18 ). In adult patients with hemato-oncological diseases and COVID-19, results were similar to the ones found in adults free of cancer ( 19 , 20 ).…”

Comorbid Asthma Increased the Risk for COVID-19 Mortality in Asia: A Meta-Analysis

“…After that, 300 articles were evaluated for full-text eligibility, and 197 articles with available data but not Asian were excluded. Ultimately, 103 studies conducted in Asia were enrolled in this meta-analysis [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 ,…”

Changing the Surgical Approach to Breast Diseases During the COVID-19 Pandemic Period

“…Findings accumulated since the pandemic suggest that cancer patients are at a higher risk for COVID-19 infections and have higher morbidity and mortality than the general population [ 11 ]. In a study involving 28 cancer patients, it was observed that these patients had twice the risk of COVID-19 infections when compared to the general population [ 12 ].…”